Department of Oral and Maxillofacial Surgery, Hamadan University of Medical Sciences, Hamadan, Iran; Dental Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Department of Pathology, Hamadan University of Medical Sciences, Hamadan, Iran.
J Craniomaxillofac Surg. 2020 Mar;48(3):211-216. doi: 10.1016/j.jcms.2020.01.006. Epub 2020 Jan 21.
This study was performed to evaluate the effects of teriparatide therapy on mandibular fracture healing in a rat model.
A unilateral mandibular fracture, 5 mm posterior to the last molar tooth, was surgically created in 120 rats. Half of the animals received a daily subcutaneous injection of 2 μg/kg teriparatide while the control rats received normal saline, starting from the day of surgery until sacrifice. Twenty rats from each group were sacrificed on postoperative days 10, 20, and 30. The healing process was evaluated histologically and scored using a grading system (ranging from 1 to 10).
On day 10 the fracture gaps of the control and teriparatide groups were mainly filled with fibrous tissue and new trabecular bone, respectively. On day 20 a large amount of new trabecular bone and some areas of fibrocartilaginous tissue were seen in the fracture gaps of the control rats. In the teriparatide group the fracture area was entirely filled with trabecular bone, which in some areas had been replaced by mature bone. On day 30 the fracture gaps of the control group were entirely bridged by new trabecular bone, while in the teriparatide group they was predominantly filled with mature bone. At all three time-points the mean healing scores for the teriparatide group (6.20 ± 0.70, 8.50 ± 0.69, and 9.85 ± 0.37, respectively) were significantly higher (p < 0.001) than for the control group (4.90 ± 0.55, 7.15 ± 0.59, and 8.90 ± 0.64, respectively).
Based on the results of this study, teriparatide should be tested in humans in order to establish whether comparable results can be achieved.
本研究旨在评估特立帕肽治疗对大鼠下颌骨骨折愈合的影响。
在 120 只大鼠中，通过手术在最后一颗磨牙后 5 毫米处造成单侧下颌骨骨折。一半的动物从手术当天开始，每天接受 2μg/kg 的特立帕肽皮下注射，而对照组大鼠接受生理盐水注射，直到处死。每组各有 20 只大鼠分别于术后第 10、20 和 30 天处死。通过组织学评估和使用评分系统（范围为 1 至 10）对愈合过程进行评分。
在第 10 天，对照组和特立帕肽组的骨折间隙主要分别填充纤维组织和新的小梁骨。在第 20 天，对照组大鼠骨折间隙中可见大量新的小梁骨和一些纤维软骨组织区域。在特立帕肽组中，骨折区域完全被小梁骨填充，在某些区域已被成熟骨取代。在第 30 天，对照组的骨折间隙完全由新的小梁骨桥接，而在特立帕肽组中则主要由成熟骨填充。在所有三个时间点，特立帕肽组的平均愈合评分（分别为 6.20±0.70、8.50±0.69 和 9.85±0.37）均显著高于对照组（分别为 4.90±0.55、7.15±0.59 和 8.90±0.64）（p<0.001）。
基于本研究结果，特立帕肽应该在人体中进行测试，以确定是否可以获得类似的结果。
